INSERT
Rohit Kashyap, M.D.
1111 Exposition Blvd., Suite 300
Sacramento, CA 85815
Ph: 916-564-6232
Fax: 916-564-6242
Send an Email to: Dr. Kashyap

Position:


Interventional & Clinical Nephrologist, Capital Nephrology Medical Group - July 2008 to Present


Licensure:


California - Active
Ohio - Active
West Virginia - Inactive


Certification:


ABIM Board Certified in Nephrology
ASDIN Certification
X-ray Supervisor & Operator Permit


Nephrology Fellowship:


Ohio State University Medical Center, Columbus, Ohio - July 2006 to June 2008



Internship and Residency:


Wright State University, Internal Medicine, Dayton, Ohio Chief Resident in final year of residency July 1996 to June 1999


Medical School:


University College of Medical Sciences, Delhi, India June 1989 to January 1995


Work Experience:


Nephrologist - Capital Nephrology Medical Group, Sacramento, CA
Internal Medicine Hospitalist - Ohio State University Hospitals East, Columbus, Ohio (with HMG) - June 2003 to June 2006

Internal Medicine practice - Holzer Medical Center and Holzer Family Care Center, Jackson, Ohio - August 2001 to May 2003

Internal Medicine practice - Veterans Memorial Hospital and Clinic, Pomeroy, Ohio - October 1999 to July 2001


Certificate of Completion:


The National Institutes of Health (NIH) Office of Extramural Research Certifies that Rohit Kashyap Successfully Completed the NIH Web-Based Training Course "Protecting Human Research Participants."


Selected Clinical Trials:


A Phase III, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Trial Evaluating the Efficacy and Safety of XXX in Adult Patients on Chronic Haemodialysis.

A Phase III , Randomized, Active-Controlled, Open-label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Haemodialysis Patients previously treated with Epogen.

A Phase-IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX.

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, to Evaluate the Safety and Efficacy Of XXX in Patients with Nephropathy Due to Type 2 Diabetes.

Patient Focus Group for Qualitative Assessment of Anemia Associated with Chronic Kidney Disease.

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of XXX in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease who are on Dialysis and who have Inadequate Glycemic Control.

A Phase II Study of the Satety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure on Haemodialysis, or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.